RU2020102713A3 - - Google Patents

Download PDF

Info

Publication number
RU2020102713A3
RU2020102713A3 RU2020102713A RU2020102713A RU2020102713A3 RU 2020102713 A3 RU2020102713 A3 RU 2020102713A3 RU 2020102713 A RU2020102713 A RU 2020102713A RU 2020102713 A RU2020102713 A RU 2020102713A RU 2020102713 A3 RU2020102713 A3 RU 2020102713A3
Authority
RU
Russia
Application number
RU2020102713A
Other versions
RU2766176C2 (ru
RU2020102713A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2020102713A3 publication Critical patent/RU2020102713A3/ru
Publication of RU2020102713A publication Critical patent/RU2020102713A/ru
Application granted granted Critical
Publication of RU2766176C2 publication Critical patent/RU2766176C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
RU2020102713A 2017-07-04 2018-07-04 Применение изовалерил-спирамицина i, ii и/или iii при изготовлении препарата для лечения и/или профилактики опухоли и получения лекарственного препарата RU2766176C2 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201710537958 2017-07-04
CN201710537958.8 2017-07-04
CN201711497546 2017-12-27
CN201711497546.2 2017-12-27
CN201711450396.X 2017-12-27
CN201711450300.X 2017-12-27
CN201711450396 2017-12-27
CN201711450300 2017-12-27
PCT/CN2018/094504 WO2019007368A1 (zh) 2017-07-04 2018-07-04 异戊酰螺旋霉素i、ii和/或iii在制备治疗和/或预防肿瘤药物方面的应用和药物

Publications (3)

Publication Number Publication Date
RU2020102713A3 true RU2020102713A3 (ru) 2021-08-04
RU2020102713A RU2020102713A (ru) 2021-08-04
RU2766176C2 RU2766176C2 (ru) 2022-02-08

Family

ID=64950608

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020102713A RU2766176C2 (ru) 2017-07-04 2018-07-04 Применение изовалерил-спирамицина i, ii и/или iii при изготовлении препарата для лечения и/или профилактики опухоли и получения лекарственного препарата

Country Status (12)

Country Link
US (1) US20200163984A1 (ru)
EP (1) EP3639829B1 (ru)
JP (1) JP7060631B2 (ru)
KR (1) KR102375444B1 (ru)
CN (1) CN110869027B (ru)
AU (1) AU2018298187A1 (ru)
CA (1) CA3068921A1 (ru)
DK (1) DK3639829T3 (ru)
ES (1) ES2912734T3 (ru)
MX (1) MX2019015676A (ru)
RU (1) RU2766176C2 (ru)
WO (1) WO2019007368A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019209740A1 (en) 2018-01-19 2020-09-10 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Use of carrimycin or active ingredient thereof
AU2019209738A1 (en) * 2018-01-19 2020-09-10 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. MTOR inhibitor, pharmaceutical composition and use thereof
JP2022540291A (ja) * 2019-05-16 2022-09-15 沈陽福洋医薬科技有限公司 線維化を予防、緩和及び/又は治療するための薬物、組成製品及びその応用
US11351185B2 (en) 2020-03-11 2022-06-07 Asclea Corporation Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis
CN113577086B (zh) * 2020-04-30 2023-05-02 沈阳福洋医药科技有限公司 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用
CN113372397A (zh) * 2021-06-22 2021-09-10 天方药业有限公司 一种己二酸螺旋霉素的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1540397A (en) * 1976-12-08 1979-02-14 May & Baker Ltd Spiramycin esters
CA2127578A1 (en) * 1993-07-08 1995-01-09 Keiichi Ajito 16-membered macrolide derivatives and process for producing the same
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
WO2007144876A1 (en) * 2006-06-12 2007-12-21 Ramot At Tel-Aviv University Ltd. Methods for treating cancer
CN101362784A (zh) * 2008-10-06 2009-02-11 山东大学 埃博霉素苷类化合物和以其为活性成分的组合物及其应用
CN101773510B (zh) 2010-03-09 2013-06-05 沈阳同联集团有限公司 异戊酰螺旋霉素iii的分离制备
CN101785778A (zh) * 2010-03-09 2010-07-28 沈阳同联集团有限公司 异戊酰螺旋霉素i的分离制备及其应用
CN101785779B (zh) 2010-03-09 2014-03-05 沈阳同联集团有限公司 异戊酰螺旋霉素ii的分离制备
RU2647237C1 (ru) * 2010-05-25 2018-03-14 Шенянг Фуянг Фармасьютекал Технолоджи Ко.Лтд. Левоизовалерилспирамицин iii, препараты, способ приготовления и употребления
CN102229634B (zh) * 2010-05-25 2014-05-28 沈阳同联集团有限公司 左旋异戊酰螺旋霉素i、其制剂、制备方法及应用
CN102247396B (zh) * 2010-05-25 2014-05-28 沈阳同联集团有限公司 左旋可利霉素、其药物组合物、制备方法及应用
US11077126B2 (en) * 2017-04-06 2021-08-03 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Use of carrimycin and pharmaceutically acceptable salts of carrimycin in manufacturing medicament for treating and/or preventing tumor

Also Published As

Publication number Publication date
MX2019015676A (es) 2022-03-17
EP3639829B1 (en) 2022-02-09
AU2018298187A1 (en) 2020-02-06
JP2020528047A (ja) 2020-09-17
KR20200024280A (ko) 2020-03-06
JP7060631B2 (ja) 2022-04-26
EP3639829A1 (en) 2020-04-22
CN110869027A (zh) 2020-03-06
KR102375444B1 (ko) 2022-03-17
RU2766176C2 (ru) 2022-02-08
CN110869027B (zh) 2023-09-08
ES2912734T3 (es) 2022-05-27
RU2020102713A (ru) 2021-08-04
WO2019007368A1 (zh) 2019-01-10
US20200163984A1 (en) 2020-05-28
EP3639829A4 (en) 2020-06-24
CA3068921A1 (en) 2019-01-10
DK3639829T3 (da) 2022-05-16

Similar Documents

Publication Publication Date Title
BR122021024397A2 (ru)
BR122021023687A2 (ru)
BR122021000189A2 (ru)
BR122022025811B8 (ru)
BR112019008823A2 (ru)
BR112020006084A8 (ru)
BR122021014832A2 (ru)
BR202018014992U2 (ru)
BR122022003520A2 (ru)
BR112020008820A2 (ru)
BR202017025154U2 (ru)
BR102017023327A2 (ru)
BR202017021228U2 (ru)
BR202017020981U2 (ru)
BR202017017068U2 (ru)
BR202017016984U2 (ru)
BR202017016924U2 (ru)
BR102017015495A2 (ru)
BR102017015250A2 (ru)
BR102017014430A2 (ru)
BR202017012548U2 (ru)
BR202017011220U2 (ru)
BR202017010814U2 (ru)
BR202017010373U2 (ru)
BR202017009870U2 (ru)